Clearwater, Florida — Acacia Diversified Holdings, Inc. (OTCQB: ACCA) (the “Company”) today announced that its wholly-owned Canna-Cures Research & Development Center, Inc. subsidiary (Canna-Cures), has launched its first research and development center in Colorado with plans to open a second center in Florida in the upcoming months.
In conjunction with that opening, Canna-Cures officially launched the Dahlia’s Botanicals Endocannabinoid Nutraceuticals product line for in-store purchases and anticipates online availability in the near future. A portion of the proceeds from our Dahlia’s Botanicals line will be awarded to the Canna Moms 501(c)(3) organization in support of its continuing public education and awareness campaign.
Canna-Cures will continue to play a major role in Acacia’s distillation and formulation of Cannabis extracts with a vision and focus on filing medical patents relating to the methodology and formulation of its products as the Company’s MariJ Pharmaceuticals subsidiary continues moving forward with its cannabis oil extraction and processing operations.
Rick Pertile, President and CEO of Acacia said: “The timing was right to open our centers and to provide support to the Canna Moms movement while simultaneously treating seizures in children with our high-quality hemp extract CBD tinctures. It has been a long wait for the right timing and location of our initial openings, but we believe this is it!”
The Company is currently engaged in an offering of its Common stock and convertible debentures to fund the forward expansion and growth of its two subsidiary operations.
Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Acacia or MariJ Pharmaceuticals websites does not constitute a part of this release.
Mr. Richard K. Pertile, CEO
Canna-Cures Research & Development Center, Inc.
MariJ Pharmaceuticals, Inc.
(Acacia Diversified Holdings, Inc. companies)
13575 58th Street North – #138
Clearwater, FL 33760
Office: (727) 678-4420 Fax: (877) 513-6295